4 citations
,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
2 citations
,
January 2015 in “Springer eBooks” Early diagnosis and aggressive treatment are crucial for Cicatricial Alopecia, and treatment effectiveness varies among patients.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
65 citations
,
January 2005 in “American journal of clinical dermatology” Children with scalp fungal infections need proper diagnosis and treatment, usually with antifungal medications, and newer drugs may offer quicker recovery.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
15 citations
,
April 2011 in “Pediatric Nephrology” New treatments for lupus show promise, but more research is needed, especially for children.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
1 citations
,
July 2022 in “British Journal of Dermatology” Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
1 citations
,
December 2014 Some drugs have gained approval for new uses, while others like tricyclic antidepressants and aspirin show promise but aren't yet approved for these uses.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
November 2023 in “Journal of Pakistan Society of Internal Medicine.” Methotrexate is effective for rheumatoid arthritis but can cause side effects.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
July 2025 in “Jurnal Farmasi Sains dan Praktis” Most adverse reactions to the treatment were mild, with nausea being the most common.
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
1 citations
,
January 2017 in “Expert opinion on orphan drugs” Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
7 citations
,
October 2022 in “Expert opinion on emerging drugs” New drugs for alopecia areata show promise but aren't universally effective, and hair loss often returns after stopping treatment.
July 1993 in “Inpharma Weekly” Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.
Baricitinib effectively regrows hair in severe alopecia areata cases.
8 citations
,
July 2024 in “Children” Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.